Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.58 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.58 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.58 |
| ▸ | CPB2 | Q96IY4 | 9/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.51 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711266 | 1.00 | ERAP2 (0.58) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL1711264 | 1.00 | ERAP2 (0.58) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL29714923 | 1.00 | ERAP2 (0.58) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL29496718 | 1.00 | ERAP2 (0.58) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL10928123 | 1.00 | ERAP2 (0.58) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL29898192 | 0.97 | ERAP2 (0.56) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL29714947 | 0.96 | ERAP2 (0.55) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL30785147 | 0.96 | ERAP2 (0.55) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL29543277 | 0.95 | ERAP2 (0.54) | ERAP2ERAP1LNPEPCPB2FOLH1 | |
| SCHEMBL31287939 | 0.95 | ERAP2 (0.54) | ERAP2ERAP1LNPEPCPB2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230414699-A1 | TREATMENT OF DERMATOLOGICAL CONDITIONS | MC2 THERAPEUTICS LTD (GB) | 2023-12-28 | — | — | US | disclosed |
| EP-4225293-A1 | TREATMENT OF DERMATOLOGICAL CONDITIONS | MC2 Therapeutics Limited (GB) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022074228-A1 | TREATMENT OF DERMATOLOGICAL CONDITIONS | MC2 THERAPEUTICS LTD (GB) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414699-A1 | TREATMENT OF DERMATOLOGICAL CONDITIONS | PRKDC, DPM1, MMP8 | ERAP2 1073/4885ERAP1 1348/4885LNPEP 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.